TrialThe Lancet. Infectious diseases2025

Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9-14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial.

Tsiri Agbenyega et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.